Arginine

Arginine

SCHEMBL5660963

CC(C)(Oc1cccc(OCCCOc2ccc(OS(C)(=O)=O)cc2)c1)C(=O)O.N=C(N)NCCC[C@H](N)C(=O)O

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACE

The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 11/20 0.41
▸ PPARD Q03181 4/20 0.41
▸ PPARG P37231 12/20 0.38
▸ MTNR1A P48039 1/20 0.36
▸ MTNR1B P49286 1/20 0.36
▸ CYP4F2 P78329 2/20 0.36
▸ CYP4A11 Q02928 2/20 0.36
▸ ALOX5 P09917 1/20 0.34
▸ EGLN2 Q96KS0 1/20 0.34
▸ F2 P00734 1/20 0.34
▸ PLG P00747 1/20 0.34
▸ PRSS1 P07477 1/20 0.34
▸ PRSS2 P07478 1/20 0.34
▸ C1S P09871 1/20 0.34
▸ PRSS3 P35030 1/20 0.34
▸ F10 P00742 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Arginine SCHEMBL5662519 1.00 PPARA (0.41) PPARAPPARDPPARGMTNR1AMTNR1B
Arginine SCHEMBL5658603 0.97 PPARA (0.40) PPARAPPARDPPARGMTNR1AMTNR1B
Arginine SCHEMBL5658599 0.97 PPARA (0.40) PPARAPPARDPPARGMTNR1AMTNR1B
Arginine SCHEMBL5662385 0.93 PPARG (0.39) PPARAPPARDPPARG
Arginine SCHEMBL5660656 0.93 PPARG (0.39) PPARAPPARDPPARG
Arginine SCHEMBL5660445 0.91 PPARG (0.47) PPARAPPARDPPARGMTNR1AMTNR1B
Arginine SCHEMBL5660450 0.91 PPARG (0.47) PPARAPPARDPPARGMTNR1AMTNR1B
SCHEMBL5662525 0.88 MTNR1A (0.34) PPARAPPARDMTNR1AMTNR1BF2
SCHEMBL5658608 0.84 PPARA (0.33) PPARAPPARDPPARGMTNR1AMTNR1B
SCHEMBL5659323 0.82 PPARA (0.54) PPARAPPARDPPARGCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093476-A1 Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them DR. REDDY'S LABORATORIES LIMITED (IN) 2007-04-26 — — US claimed
US-20070093476-A1 Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them DR. REDDY'S LABORATORIES LIMITED (IN) 2007-04-26 — — US disclosed
EP-1680397-A2 NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dr. Reddy's Laboratories Ltd. (IN) 2006-07-19 — — EP disclosed
WO-2005040102-A2 NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S LABORATORIES LTD. (IN) 2005-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093476-A1 Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them GPR119, NR1H3, NR1H2 PPARA 251/4885PPARD 153/4885PPARG 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback